Cryo Cell International Inc key statistics and ratios

In fiscal 2025, Cryo Cell International Inc had an operating margin of 1.5% and a current ratio of 0.59. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Cryo Cell International Inc: financial ratios, annual
Fiscal year	2010Nov 2010	2011Nov 2011	2012Nov 2012	2013Nov 2013	2014Nov 2014	2015Nov 2015	2016Nov 2016	2017Nov 2017	2018Nov 2018	2019Nov 2019	2020Nov 2020	2021Nov 2021	2022Nov 2022	2023Nov 2023	2024Nov 2024	2025Nov 2025	LTMAug 2026
Gross margin	—	—	—	—	—	—	—	73.5%	70.8%	68.5%	69.0%	68.9%	71.0%	73.2%	75.2%	76.6%	78.5%
Operating margin	18.8%	−1.5%	−9.5%	9.0%	9.8%	13.9%	1.9%	19.7%	17.8%	15.9%	24.6%	13.9%	13.3%	−39.3%	10.9%	1.5%	0.6%
Net margin	19.5%	−11.7%	−35.1%	0.1%	2.8%	38.4%	−5.7%	9.1%	−2.9%	7.2%	11.6%	7.2%	9.1%	−30.4%	1.3%	−7.7%	−6.2%
Free-cash-flow margin	10.9%	1.7%	1.3%	2.5%	7.1%	22.5%	20.1%	22.1%	16.7%	17.7%	26.9%	21.1%	−11.9%	6.6%	11.3%	16.6%	14.9%
Return on assets	19.1%	−11.2%	−39.7%	0.2%	5.1%	54.6%	−6.8%	10.7%	−2.6%	5.3%	8.1%	3.9%	4.4%	−14.7%	0.6%	−3.8%	−3.1%
Asset turnover	0.98	0.95	1.13	1.59	1.85	1.42	1.18	1.17	0.87	0.74	0.70	0.54	0.48	0.48	0.49	0.50	0.50
Current ratio	1.56	1.33	0.87	0.96	0.93	0.99	0.69	0.91	0.96	1.00	1.13	0.75	0.49	0.45	0.58	0.59	0.86
Debt to equity	—	—	—	—	—	—	—	—	—	—	—	90.7%	—	—	—	—	—
Interest cover (operating income ÷ interest)	2.6x	n/m	n/m	1.2x	1.7x	2.2x	0.5x	3.8x	3.4x	3.0x	5.0x	2.9x	2.6x	n/m	1.9x	0.2x	0.1x
Effective tax rate	—	—	—	86.1%	18.2%	—	—	36.1%	—	32.5%	28.1%	20.2%	16.5%	—	85.7%	—	—
R&D as % of revenue	0.7%	1.0%	0.6%	0.2%	0.3%	0.2%	0.2%	0.2%	0.3%	0.1%	0.1%	0.2%	1.3%	3.7%	3.9%	1.2%	1.0%
SG&A as % of revenue	53.4%	69.3%	80.3%	59.8%	60.9%	58.7%	63.7%	53.1%	53.5%	46.8%	45.9%	50.6%	51.4%	54.8%	57.9%	57.7%	60.6%
Capital spending as % of revenue	2.2%	2.8%	0.7%	1.8%	0.6%	0.5%	1.5%	0.4%	1.5%	2.1%	0.3%	6.3%	40.1%	21.8%	7.5%	0.7%	0.9%
Free cash flow ÷ net income	56.0%	—	—	>999%	259.1%	58.5%	—	242.7%	—	245.9%	230.8%	292.4%	−129.7%	—	897.1%	—	—
Dividends ÷ net income	—	—	—	—	—	—	—	—	—	—	—	0.0%	276.9%	—	502.5%	—	—
Dividends and buybacks ÷ free cash flow	—	—	749.0%	156.4%	186.2%	67.6%	232.6%	7.9%	—	17.6%	—	4.1%	—	38.4%	95.5%	64.8%	0.0%

US$ thousands unless shown otherwise. Fiscal quarters.

Cryo Cell International Inc: financial ratios, quarterly
Quarter	2024 Q4Nov 2024	2025 Q1Feb 2025	2025 Q2May 2025	2025 Q3Aug 2025	2025 Q4Nov 2025	2026 Q1Feb 2026	2026 Q2May 2026	2026 Q3Aug 2026
Gross margin	79.6%	75.1%	76.6%	77.0%	77.9%	78.4%	78.4%	79.4%
Operating margin	−1.5%	13.3%	18.8%	24.3%	−50.6%	10.0%	15.4%	28.0%
Net margin	−23.2%	3.5%	4.5%	9.6%	−48.7%	0.6%	7.1%	16.2%
Free-cash-flow margin	26.8%	11.2%	8.1%	31.9%	15.5%	7.6%	23.3%	13.3%
Current ratio	0.58	0.58	0.60	0.63	0.59	0.62	0.71	0.86
R&D as % of revenue	3.8%	1.2%	1.7%	0.8%	1.1%	0.9%	1.3%	0.7%
SG&A as % of revenue	74.9%	58.2%	53.7%	49.5%	69.5%	65.2%	59.4%	48.3%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

1 of 5 checks passed · August 31, 2026

What it owns · $62m

Short-term assets $13mLonger-term assets $49m

What it owes, and who funded it · $79m

Short-term liabilities $15mLonger-term liabilities $63mShareholders' equity $-16m

Short-term assets cover short-term liabilities $13m of assets due within a year against $15m of liabilities due within a year.
Short-term assets cover long-term liabilities $13m short-term assets against $63m of longer-dated liabilities.
More cash than debt $1m of cash against $8m of debt.
Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
A year's operating cash flow covers at least 20% of debt $5m of operating cash flow against $8m of debt.
Operating profit covers interest at least five times over Operating income of $189,419 against $2m of interest.

From Cryo Cell International Inc's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

73 /100

Strong moat

How hard Cryo Cell International's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

Returns on capital 20 / 20

Cash operating profit has been a median 16.8% of total assets over 9 years.
Pricing power 19 / 20

Gross margin has been a median 72.3%, moving by 3.5 percentage points (standard deviation) across 9 years.
Durability 4 / 20

Operating margin has been a median 14.8%; its worst year was -39.5%.
Cash conversion 18 / 20

Free cash flow was positive in 9 of 10 years, at a median 18.2% of revenue.
Discipline 18 / 20

The diluted share count fell 3.8% over five years; stock-based pay has been a median 1.8% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (78 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: AMS vs CCEL CCEL vs HAO AHG vs CCEL

More: Health Care Services stocks compared, Health Care sector, rankings of US companies

Figures from Cryo Cell International Inc's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Cryo Cell International Inc.